INSM250117P82500
- 0.00
- 0.000.00%
Insmed Newsroom
TD Cowen Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $98
The Five-year Returns Have Been Solid for Insmed (NASDAQ:INSM) Shareholders Despite Underlying Losses Increasing
Optimistic Buy Rating for Insmed Driven by Promising Drug Launch and Strategic Positioning
Analysts Are Bullish on These Healthcare Stocks: UnitedHealth (UNH), Insmed (INSM)
Insmed Insider Sold Shares Worth $2,711,456, According to a Recent SEC Filing
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Gilead Sciences (GILD) and Abbott Laboratories (ABT)
Insmed's Gene Therapy Poised to Challenge DMD Landscape After IND Clearance
Health Check: How Prudently Does Insmed (NASDAQ:INSM) Use Debt?
How Is The Market Feeling About Insmed?
Evercore Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $75
Insmed (INSM) Gets a Buy From Evercore ISI
Truist Financial Maintains Insmed(INSM.US) With Buy Rating
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $85
Insmed's Promising Growth: Buy Rating Backed by Strong Performance and Strategic Advancements
TD Cowen Maintains Insmed(INSM.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Insmed (INSM)
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Insmed Issues Preliminary Revenue Results, Guidance for Arikayce
Insmed Projects Revenue Growth and Advances Drug Pipeline
Express News | Insmed Inc: Narrowing Timing for Expected U.S. Launch for Brensocatib in Bronchiectasis to Q3 of 2025